Citation:Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al 2015
From Cancer Guidelines Wiki
Citation
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015 Oct;16(13):1306-15 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26338525.
Critical appraisals